DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Townsquare Capital LLC

Townsquare Capital LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 288.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,191 shares of the medical device company's stock after purchasing an additional 27,623 shares during the quarter. Townsquare Capital LLC's holdings in DexCom were worth $2,892,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Crux Wealth Advisors bought a new position in shares of DexCom in the 4th quarter valued at $245,000. Qtron Investments LLC acquired a new position in DexCom during the fourth quarter worth about $766,000. Grandeur Peak Global Advisors LLC raised its stake in DexCom by 20.5% during the fourth quarter. Grandeur Peak Global Advisors LLC now owns 63,420 shares of the medical device company's stock worth $4,932,000 after acquiring an additional 10,795 shares in the last quarter. Covestor Ltd boosted its stake in shares of DexCom by 15.6% in the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares in the last quarter. Finally, Treasurer of the State of North Carolina increased its position in DexCom by 9.9% during the 4th quarter. Treasurer of the State of North Carolina now owns 263,407 shares of the medical device company's stock worth $20,485,000 after purchasing an additional 23,810 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 105,009 shares of company stock worth $8,044,178. Insiders own 0.32% of the company's stock.

DexCom Price Performance

DXCM traded down $0.14 on Friday, hitting $68.59. 3,702,730 shares of the company's stock traded hands, compared to its average volume of 4,216,911. The firm has a market cap of $26.90 billion, a price-to-earnings ratio of 47.97, a P/E/G ratio of 2.30 and a beta of 1.50. The company's 50 day simple moving average is $75.33 and its 200-day simple moving average is $76.59. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DXCM. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup raised their target price on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Morgan Stanley raised their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Finally, Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.